Community consensus suggests this combination produces roughly 60% better outcomes than either peptide alone for joint and soft tissue problems
Review current FDA warnings and understand this peptide is NOT approved or regulated as a treatment
Baseline Laboratory Assessment Before initiating GHK-Cu therapy, obtain: Serum copper level (normal range: 70 to 140 mcg/dL) Ceruloplasmin (normal range: 20 to 35 mg/dL) 24-hour urine copper (to exclude copper overload states) Hepatic function panel (AST, ALT, alkaline phosphatase, total bilirubin) Complete blood count with differential Wound photography and planimetric measurement (length, width, area) Wound culture if signs of infection are present Patients with Wilson disease, known copper storage disorders, or hepatic cirrhosis should not receive exogenous copper peptides [13]
Patel told Glossy
The results demonstrated a significant increase in the abundance of beneficial butyrate-producing bacteria, such as Faecalibacterium and Anaerobutyricum , in the gut microbiota of the intervention group
Tesamorelin Tesamorelin boosts GH release, which can change body composition and improve metabolic health